19 patents currently held
2 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
5 more records may belong here and await a decision; they are not counted.
The next term ends in Feb 2040. from the record
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
0
Ending by 2030
Feb 2040
Next term end
16
Patent families
When these terms end
Held patents by the year their term ends
notable patents
all others
Updated Nov 16, 2026 · includes USPTO assignment & status data published Nov 16, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size.
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Ends Feb 2040 · Medium confidence
Also notable
Ends Feb 2040 · Low confidence
Also notable
Ends Feb 2040 · Medium confidence
Compositions and Methods for Treating Hemoglobinopathies
US 11,344,609
Cited by 5 later US patents, top 25% of utility patents granted in 2022 in our data. Protection runs to 2040.
Adenosine Deaminase Base Editors and Methods of Using Same to Modify a Nucleobase in a Target Sequence
US 11,155,803
The most cited patent in this portfolio, cited by 14 later US patents, top 25% of utility patents granted in 2021 in our data. Protection runs to 2040. A terminal disclaimer caps this term to an earlier patent's.
Compositions and Methods for Treating ALPHA-1 Antitrypsin Deficiency
US 12,622,931
A family of 5 related applications built on the 2026 grant. Too new for citation comparison; protection runs to 2040. A terminal disclaimer caps this term to an earlier patent's.
Formerly held, still cited
Notable
Ends Apr 2039 · High confidence
The most cited patent in this portfolio, cited by 68 later US patents, top 1% of utility patents granted in 2023 in our data. Protection runs to 2039.
now held by The Broad Institute, Inc.
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Mar 12, 2027The maintenance fee for Compositions and Methods for Treating Hemoglobinopathies (US 11,752,202) comes due Mar 12, 2027. Unpaid by Sep 13, 2027, it lapses early.
Recent changes
- 3 of the patents on this record were granted since Aug 18, 2026
What they patent
The 5 largest of its 16 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.
| Compositions and Methods for Treating Hemoglobinopathies | 4 in force | to Feb 2040 |
| Nanomaterials Comprising Triols | 1 in force | to Jul 2043 |
| Nucleobase Editors Having Reduced Non-Target Deamination and Assays for Characterizing Nucleobase Editors | 1 in force | to Jul 2043 |
| Nanomaterials Comprising Acetals | 1 in force | to May 2043 |
| Methods of Editing Single Nucleotide Polymorphism Using Programmable Base Editor Systems | 1 in force | to Apr 2043 |
Patents held now
Soonest term end first.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 11,142,760 | Compositions and Methods for Treating Hemoglobinopathies In force · Medium confidence | In force | Medium confidence | |
| US 11,155,803 | Adenosine Deaminase Base Editors and Methods of Using Same to Modify a Nucleobase in a Target Sequence In force · Low confidence | In force | Low confidence | |
| US 11,344,609 | Compositions and Methods for Treating Hemoglobinopathies In force · Medium confidence | In force | Medium confidence | |
| US 11,752,202 | Compositions and Methods for Treating Hemoglobinopathies In force · Low confidence | In force | Low confidence | |
| US 12,016,908 | Compositions and Methods for Treating Hemoglobinopathies In force · Low confidence | In force | Low confidence | |
| US 12,622,931 | Compositions and Methods for Treating ALPHA-1 Antitrypsin Deficiency In force · Medium confidence | In force | Medium confidence | |
| US 12,125,145 | Systems and Methods for Implemented Mixed Reality in Laboratory Automation In force · High confidence | In force | High confidence | |
| US 12,600,971 | Modified Immune Cells Having Adenosine Deaminase Base Editors for Modifying a Nucleobase in a Target Sequence In force · High confidence | In force | High confidence | |
| US 12,767,959 | Nucleobase Editors Having Reduced Off-Target Deamination and Methods of Using Same to Modify a Nucleobase Target Sequence In force · High confidence | In force | High confidence | |
| US 12,133,884 | Methods of Substituting Pathogenic Amino Acids Using Programmable Base Editor Systems In force · High confidence | In force | High confidence |
Also on record, not counted in the 19: 2 patents in force now held by others · 87 applications pending · 2 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.